Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 ROE % is 23.83% as of Mar. 2026, which is 12% below its 10-year median of 27.04. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 938 Drug Manufacturers companies, Rubicon Research ranks better than 90.62% on this metric.
The historical rank and industry rank for Rubicon Research's ROE % or its related term are showing as below:
NSE:RUBICON'
s ROE % Range Over the Past 10 Years
Min: -5.9 Med: 27.04 Max: 29.02
Current: 23.88
During the past 4 years, Rubicon Research's highest ROE % was 29.02%. The lowest was -5.90%. And the median was 27.04%.
NSE:RUBICON's ROE % is ranked better than 90.62% of 938
companies
in the Drug Manufacturers industry
Industry Median: 6.05
vs NSE:RUBICON: 23.88
Rubicon Research (NSE:RUBICON) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Rubicon Research ROE % Related Terms
Rubicon Research ROE % Historical Data
* Premium members only.
The historical data trend for Rubicon Research's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Rubicon Research's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's ROE % distribution charts can be found below:
* The bar in red indicates where Rubicon Research's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Rubicon Research (NSE:RUBICON) has a ROE % of 23.83% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Rubicon Research and its competitors. This is 12% below median its historical median of 27.04. According to the industry distribution chart, Rubicon Research ranks #88 out of 938 companies in the Drug Manufacturers industry, placing it in the top 9.4%.
Is Rubicon Research's ROE % too high?
Rubicon Research's current ROE % of 23.83% is 12% below median its 10-year median of 27.04. The Drug Manufacturers industry median ROE % is 6.05. Rubicon Research's value of 23.83% is 293.9% above this industry median. Based on the distribution chart, Rubicon Research ranks #88 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #88 out of 938 companies for ROE %. This places Rubicon Research in the top 9% of its industry — outperforming the majority of peers. The industry median ROE % is 6.05. Rubicon Research's value of 23.83% is 293.9% above this benchmark. While the company's 10-year median is 27.04 vs. the industry median of 6.05, Rubicon Research has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.05, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current ROE % of 23.83% is 293.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current ROE % is 23.83%, which is 12% below median its own 10-year median of 27.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current ROE % of 23.83%. The current ROE % is 23.83%, which is 12% below median its 10-year median of 27.04 and 293.9% above the Drug Manufacturers industry median of 6.05. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current ROE % is 23.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
